Composite promoters combining the prostate-specific antigen (PSA) enhancer core element with promoter elements derived from gene coding for human prostate-specific transglutaminase gene, prostate-specific membrane antigen gene, prostate-specific antigen, rat probasin or phosphoglycerate kinase were characterized for their ability to specifically express the enhanced green fluorescent protein (EGFP) gene in prostate versus non-prostate cancer cell lines when transferred with a human immunodeficiency virus-1-based lentiviral vector. By themselves minimal proximal promoter elements were found to inefficiently promote relevant tissue-specific expression; in all the vectors tested, addition of the PSA enhancer core element markedly improved EGFP expression in LnCaP, a cancer prostate cell line used as a model for prostate cancer. The composite promoter was inactive in HuH7, a hepatocarcinoma cell line used as a model of neighboring non-prostate cancer cells. Among the promoters tested, the combination of the PSA enhancer and the rat probasin promoter showed both high specificity and a strong EGFP expression. Neither a high viral input nor the presence of the cPPT/CTS sequence affected composite promoter behavior. Our data suggest that composite prostatespecific promoters constructed by combining key elements from various promoters can improve and/or confer tissue specific expression in a lentiviral vector context.
Introduction
Prostate cancer is the second leading cause of cancer death in men. 1 Although the most recent data suggest that the incidence of death from this disease is on the decline owing to the advent of the prostate-specific antigen (PSA) test and subsequent early intervention, once a patient becomes hormone refractory, there are few treatment choices available. 2 Treatment options for early-stage disease include 'watchful waiting' with deferred treatment, radical surgery, radical radiotherapy, hormone therapy and combinations of these options. As all of these options have substantial drawbacks, alternative treatment strategies are urgently needed. Gene therapy approaches to prostate cancer are attractive because they allow selective targeting of the affected tissue. Selective targeting avoids toxicity associated with treatments such as cytotoxic chemotherapy, which has so far proven to be of limited benefit in prostate cancer. In addition, because the prostate is a non-essential organ that can be removed, treatment can be targeted with tissue-specific rather than tumor-specific promoters.
Tissue-specific gene regulatory sequences have important potential applications in gene therapy as they enable the targeted expression of introduced genes to specific cells, minimizing unwanted side effects of expression at other sites.
High prostate tissue specificity has been demonstrated for several promoters in plasmid vectors and may provide interesting alternatives to ubiquitous promoters. 3 Particularly promising candidate for transcriptional targeting of prostate cancer cells in vivo include promoters driving the expression of genes coding for PSA, prostatespecific membrane antigen (PSMA), human prostatespecific transglutaminase (pTG) and rat probasin. pTG is expressed in prostate and is androgen regulated, the expression being lost both in prostate cancer and most of the metastatic tumors. [4] [5] [6] Expression of PSMA was found in the epithelial cells of normal prostate independently of the presence of androgens. The PSMA promoter presents two advantages for gene therapy. First it is expressed in the tumor itself, in metastasis and also in the tumor-induced neovasculature, but not in normal blood vessels, providing a much wider use for gene therapy. [7] [8] [9] [10] [11] Second testing of 5 kb upstream sequences has shown that the first 600 bp region is sufficient to act as a minimal promoter. 12 The PSA glycoprotein is prostate specific, overexpressed in tumor, and decreased under androgen ablation conditions. 13 The proximal PSA promoter (541 bp) stimulates low-level transcription in response to androgen, although two functionally active androgen receptor-binding sites (ARE) have been identified at positions À170 (ARE-I) and À394 (ARE-II).
14 Inclusion of the upstream enhancer restricts the activity to PSAsecreting cells and confers specificity of expression. 15 This enhancer located at À4.2 kb of the PSA promoter responds to androgen and is characterized by the presence of a functionally active, moderate-to-high affinity ARE-III. 16 Rat probasin is abundantly expressed in the rat dorsolateral prostate nuclei and is regulated by androgen during development. It has been established that a 430 bp upstream region of the rat probasin gene confers prostatespecific expression to a reporter gene 17 in vitro as well as in transgenic mice. 9, [18] [19] [20] These promoters and their expression patterns would theoretically be able to target transgene expression in normal tissue, androgen-dependent stage and androgendeprived tumors, but the interaction between promoter sequences and the selected vector can dramatically affect the tissue-specific expression. In a previous study, we demonstrated that lentiviral vectors can transduce cancer prostate cells. 21, 22 The present study was designed to compare the ability of various native and composite prostate-specific promoters to express enhanced green fluorescent protein (EGFP) in a lentiviral context. The targeting strategy relied on the use of the PSA, PSMA, pTG and Probasin promoters and the PSA enhancer core (PSE) and focused on the level of EGFP expression as assessed by fluorescence-activated cell sorting (FACS) analysis in prostate and non-prostate cancer cell line models. This study has potential implications for numerous therapeutic strategies based on toxic 'suicide' gene transfer to eliminate prostate cancer cells. These strategies include the transfer of genes coding for pro-apoptotic proteins, such as p53, Bad, Bax, Fas ligand, [23] [24] [25] [26] transferred as a single gene or in combination, 26, 27 antiangiogenic factors, 28 or the diphteria toxin gene, 29 with or without additional treatments. In all these strategies, preventing toxic gene expression in healthy tissue neighboring the prostate as a function of whether the vector is injected systemically or locally is a major concern. This explains why several strategies use native prostate tissue-specific promoters such as the PSA, PSMA or androgen-regulated prostate-specific T-cell receptor gamma-chain alternate reading frame protein (TARP) promoters. 30 Our results show that among the main candidate promoters, a combination of the PSA enhancer and the rat probasin promoter exhibits both a strong specificity and a high level of expression of the transgene, and strengthens the possibility to express highly toxic therapeutic transgenes using chimeric new promoters in prostate cancer cells and tissues.
Materials and methods

Cells and medium
HuH7 cells, a hepatocarcinoma cell line, and 293T, a human embryo kidney cell line, were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Two prostate epithelial cell lines, LnCaP and PNT2C2, and a human pancreas carcinoma cell line, Panc-1 (a kind gift from Iovanna Juan, INSERM EMI 0116, Marseille), were maintained in Rosewell Park Memorial Institute media (RPMI)-1640 medium supplemented with 10% heat-inactivated FBS and 1% antibiotics (penicillin 10 000 UI/ml; streptomycin 10 000 mg/ml). For androgen regulation experiments, cells were plated in the regular culture medium for 24 h, then transduced in a DMEM-or RPMI-1640-based phenol red-free medium supplemented with 10% charcoaltreated FBS considered as a steroid-free medium. Twenty-four hours later, the medium was replaced with fresh, steroid-free medium with or without R1881 (methyltrienolone, DuPont NEN, Boston, MA), a synthetic stable and highly potent androgen, dissolved in ethanol, as indicated in Results.
Construction of lentiviral vectors
The lentiviral vector backbone used in this study was derived from pRRL-PGK-EGFPsin18, 31 a self-inactivating vector that expresses EGFP under the control of the human PGK promoter used here as a control vector. Figure 1 describes the construction strategies selected to generate the vectors used in this study. According to the insert donor plasmid name and the recipient backbone name as listed in Figure 1 , the following cloning strategies were used: PGK-PSE, cloning of the XhoI-SalI insert into the XhoI backbone; PGK þ cPPT/CTS, XhoI-EcoRI insert into XhoI-EcoRI backbone; PSMA-1, blunt-ended BglII-BamH1 into blunt-ended XhoI-BamHI; PSMA-2.5, XhoI-PstI insert into XhoI-PstI backbone; PSMA-2.5 þ PSE, XhoI-SalI insert into XhoI backbone; pTG-0.2, XhoI-blunt-ended NotI insert into XhoI-blunt-ended SalI backbone; pTG-1.4, XhoI-PinA1 insert into XhoIPinA1 backbone; pTG-1.4 þ PSE, XhoI-SalI insert into XhoI backbone; PSA-0.6, blunt-ended BglII-BamHI insert into blunt-ended XhoI-BamHI backbone; PSA-1, blunt-ended CfoI-PinA1 insert into blunt-ended BstXIPinA1 backbone; PSA-1 þ cPPT/CTS, XhoI-SalI insert into XhoI backbone; PSA-1 þ PSE, deletion by ligation of the blunt-ended BstEII-blunt-ended XhoI backbone; PSA-1 þ PSE þ cPPT/CTS, XhoI-SalI insert into XhoI backbone; PSA-1 þ 1.5, deletion by ligation of the bluntended XhoI-blunt-ended XbaI backbone; PSA-1 þ 2, XhoI-Eco47III insert into the XhoI-EcoRV backbone; PSA-3.2, AatII-PinA1 insert into the blunt-ended BstXIPinA1 backbone, PSA-3.2 þ 2.5, XhoI-NdeI insert into Xho-NdeI backbone; PSA-3.2 þ 2.5 þ cPPT/CTS, bluntended XhoI-blunt-ended SalI insert into blunt-ended NdeI backbone; Prob, 880 bp deletion by ligation of the PstI backbone; Prob þ PSE, SalI-blunt-ended BglII insert into XhoI-blunt-ended SalI; Prob þ PSE þ cPPT/CTS, NsiI-PstI insert into PstI backbone. D4prob þ PSE, constructed by deletion of the 250 bp fragment from the Prob þ PSE vector, and pEGFP-TRP-bis, constructed by insertion of the BamHI-BglII insert of the pEGFP-TRP into the pEGFP backbone (Clontech Laboratories, Palo Alto, CA) linearized at BglII, were used as intermediate constructs. pRRL-PGK-EGFPsin18 was kindly provided by D Trono (University of Geneva, Switzerland). pLucPSEProb was kindly provided by J Trapman (Erasmus University, Rotterdam, The Netherlands).
Lentiviral vector production and transduction
For viral vector production, 293T cells seeded in 225 cm 2 flasks to obtain a 70-80% confluency at day of transfection were transfected using a polyethyleneimine (PEI)-based procedure as described previously. 32, 33 The crude viral suspension was harvested from transfected 293T cell cultures 48 and 72 h after transfection, filtered (0.2 mm) and stored at À801C until use. The p24 Gag protein content was estimated by enzyme-linked . In experiments using high viral inputs, concentrated stocks resuspended in phosphate-buffered saline were generated using a polyethylene glycol-based procedure. 34 For transduction, cells were seeded in 12-well plates to obtain a 70-80% confluency on the day of transduction. Twenty-four hours later, viral vector stocks were added to the cell cultures using the same amount of p24 per cell together with polybrene at 8 mg/ml in a final volume of 0.5 ml. Sixteen hours later, viral vector-containing medium was replaced with fresh medium. Expression of EGFP was assayed by FACS at least 6-7 days after transduction when expression was determined to have plateaued based on measurement of MFI and percentage of EGFP þ cells.
Results
Lentiviral vectors driving expression of EGFP from the basal pTG, PSMA and PSA promoters are not efficient in prostate and non-prostate cell lines As a first step, a set of lentiviral vectors designed to target the expression of the EGFP marker gene in prostate cells (Figure 1 ) was constructed by inserting pTG, PSMA and PSA minimal promoters in the place of the constitutive PGK promoter that controls EGFP expression in RRL-PGK-GFP, 31 a third-generation lentiviral self-inactivating vector. The 200 bp and 1.4 kb sequences located upstream of the pTG gene transcription start site were used to construct pTG-0.2 and pTG-1.4 vectors. Two different vectors exhibiting 1 and 2.5 kb of the PSMA coding sequence in the 5 0 flanking region were used to generate PSMA-1 and PSMA-2.5, respectively. A 600 bp, 1 kb and 3.2 kb long sequence located upstream of the transcription start site was used to construct the PSA-0.6, PSA-1 and PSA-3.2 vectors, respectively.
The hormone responsive prostate cell line LnCaP and the non-prostate cell line HuH7 (human hepatocarcinoma) were used as models. Control experiments were carried out using the RRL-PGK-GFPsin18 driving constitutive and ubiquitous expression of EGFP. To standardize these experiments, vectors were produced as viral particle batches using a parallel production run strategy and the transduction experiments were performed simultaneously using a homogenous procedure as indicated in the Materials and methods section. In addition, for each set of experiments, three independent repetitions were performed in duplicate using three separate production batches. Transductions were carried out using low viral input that favors the analysis of transgene expression relative to single efficient proviral integration per cell. 21, 35 Assuming that, to a certain extent, the p24 content assessed by ELISA indirectly reflects lentiviral vector particles content, experiments were standardized by loading the same amount of p24 per transduction assay. It is noteworthy that the amount of p24 used to transduce target cells in this study was roughly correlated with a multiplicity of infection (MOI) of about 1 when using the percentage of EGFP-positive cells obtained in LnCaP transduced with RRL-PGKGFPsin18, and favorized low viral input. Assuming that MFI assayed in transduced cells by FACS correlated with the amount of autofluorescent EGFP protein and thus with the level of expression of the promoter-EGFP unit and that a variation in the number of EGFP-positive cells, even between parallel experiment, may occur independently of the promoter tested, the strength and specificity of the promoters were assessed using the MFI. The percentage of EGFP cells was only considered as a complementary parameter.
When present, EGFP expression as assessed by fluorescence microscopy and cytofluorometry was detected 24-48 h after the transduction and reached a maximum by days 6-7. All prostate promoter-containing vectors were found to express the EGFP gene at low level in comparison with the control vector that expressd the EGFP gene from the PGK constitutive promoter. As shown in Figure 2a , the pTG-0.2 and pTG-1.4 constructs were only weakly active in both the nonprostate and prostate cell lines with MFI being less than 50 and 180, respectively. The percentage of EGFPpositive cells was below 5 and 20% for pTG-0.2 and pTG-1.4, respectively.
For vectors containing the PSMA region, MFI obtained using PSMA-1 in the non-prostate cell line was the same as that obtained using pTG-0.2 and pTG-1.4 but MFI obtained using PSMA-1 in the prostate cell line was slightly lower than that obtained using pTG-1. In both the non-prostate and prostate cell lines, PSMA 2.5 was slightly less expressed than PSMA-1 with an MFI of less than 50 in HuH7 and up to 80 in LnCap ( Figure 2a ). As shown in Figure 2a , vectors containing only the basal PSA promoter region showed moderate expression equivalent to that obtained with the PSMA promotercontaining constructs in the cell lines tested. It is noteworthy that the percentage of EGFP-positive cells observed with PSA-0.6, PSA-1 and PSA-3.2 in HuH7-and LnCap-transduced cell populations decreased as the length of the basal promoter increased (Figure 2a) . Transduced cells were maintained in culture and analyzed by FACS every 4 days up to day 27. Regardless of the vector and target cell used, MFI and percentage of EGFP-positive cells increased up to day 7 and remained constant until day 27 (data not shown), suggesting a stable expression of the transgene during this period. Similar results with very low expression of the EGFP gene were obtained using the human pancreas carcinoma cell line Panc-1 described to express PSA moderately and the transformed prostate epithelial cell line, PNT2C2 (data not shown).
In conclusion, all the short prostate promoters tested can be considered as basal promoters, but the specificity and strength of expression need to be improved.
The region encompassing the PSE element can confer specific expression to a basal PSA promoter in a lentiviral context The androgen-responsive PSE element located at À4.2 kb relative to the transcription start site has been shown to be a key element to both increase the expression in prostatic tissue and reduce the low basal expression in nonprostatic tissue. 15 PSA-1 was modified accordingly by ligation of the 1 kb long basal PSA promoter to the 500 bp minimal upstream enhancer region of the PSA gene called PSE to generate PSA-1 þ PSE. Two alternatives vectors, PSA-1 þ 1.5 and PSA-1 þ 2, containing the PSE element as 1.5 or 2 kb long sequence were constructed in parallel. PSA-3.2 þ 2.5, a lentiviral vector with the entire region encompassing all these fragments, was also constructed (Figure 1) . Using these vectors, the level of EGFP expression was substantially increased in LnCaP as compared to HuH7 (Figure 2b) . In LnCaP, expression of PSA-1 þ PSE, PSA-1 þ 1.5 and PSA-1 þ 2 reached an MFI of 600 in transduced cell populations showing about 60% of EGFP-positive cells. According to MFI, all non-prostate cells remained at basal level. In our hands, PSA-3.2 þ 2.5, the vector containing the complete PSA promoter in the lentiviral backbone,showed only a poor level of expression in vitro. The MFI was about 200, which is comparable to that obtained with PSA-1 basal promoter in LnCaP in association with a very low percentage of EGFP-positive cells.
These experiments show that, in a lentiviral vector context, when the PSA enhancer is used as a complementary element of the basal PSA promoter, higher levels of prostate cell-specific expression can be achieved.
The PSE element can confer prostate cancer-specific expression to non-PSA promoters Assuming that enhancer activity driven by the PSE element can modify expression of non-PSA basal promoters, the PGK promoter in the RRL-PGK-GFPsin18 was replaced with chimeric promoters, constructed by fusing the 500 bp PSE with the basal promoters tested in the previous experiments and selected on the basis of low basal expression in the non-prostate cell lines. The enhancer was therefore cloned in the sense orientation upstream of the 1.4 kb pTG promoter and the 2.5 kb PSMA to generate pTG-1.4 þ PSE and PSMA-2.5 þ PSE, respectively. The impact of the PSA enhancer was tested both as an additional element of a constitutive promoter, using the PGK promoter as a model in PGK-PSE, and as an androgen-regulated promoter specifically expressed in the prostate using the rat probasin promoter in Prob þ PSE (Figure 1) . 19, 36 Lentiviral vector particles were then produced and evaluated to determine their ability to drive prostate-specific expression of EGFP as assessed by the MFI using PSA-1 þ PSE as a standard (Figure 3a) . The percentage of EGFP-positive cells was also evaluated (Figure 3b) .
Combination of the pTG promoter with the PSA enhancer in pTG-1.4 þ PSE did not affect EGFP gene expression, in either HuH7 or LnCap that continued to show basal-level expression. Conversely, when combined with the PSMA promoter in PSMA-2.5 þ PSE, the PSE conferred tissue-specific expression with low expression in HuH7 and strong expression in LnCaP. This pattern was similar to that observed with PSA-1 þ PSE combining the PSA enhancer and the PSA basal promoter. When fused to the ubiquitous PGK promoter in PGK þ PSE, the PSE also induced an increased expression level in LnCaP but PSA enhancer core element in lentiviral vectors S Chapel-Fernandes et al had no effect on expression in the non-prostate cell line HuH7. Relevant tissue specificity was observed in Prob þ PSE combining the PSE element with the probasin promoter region. Expression in non-prostate cells remained undetectable, whereas strong expression with an MFI of 2500 was observed in prostate cells. For comparison, it should be recalled that MFI never exceeded 400 in prostate cells whatever the vector used. These experiments demonstrate that the PSE element can confer prostate-specific expression to lentiviral vectors designed to express the transgene from heterologous basal promoters. Expression can be modulated in terms of both specificity and strength when associated with prostate-specific promoter or only strength when associated with a ubiquitous promoter in prostate cells.
Viral input-dependent increase in the percentage of transduced cells does not affect tissue-specific expression of the PSE element-containing chimeric promoters Analysis of specificity of expression must be carried out in low-viral input context with an MFI characterized by expression of only one vector copy per cell. After intratumoral injection, diffusion of the lentiviral vector induces a decreasing gradient of multiplicity of infection from the injection site to the front edge of the diffusing product, thus favoring multiple rounds of transduction in cells close to the injection site. To assess the in vivo potential of the constructs described previously, in vitro experiments were also performed with viral inputs featuring increasing MOI.
Expression of vectors combining the PSE with either the PSA, PSMA or probasin basal promoters was subsequently tested with increasing amounts of lentivirus assayed by p24 levels. Based on the RRL-PGK-GFPsin18 virus, a p24 dose of 4, 40 and 400 ng per 0.75 Â 10 5 cells was roughly equivalent to an MOI of 0.2, 2 and 20, respectively, when using LnCaP as target cells. Four days after transduction, the cells were observed by fluorescence microscopy and FACS was used to determine both level of expression and percentage of EGFP-positive cells (Figure 4a and b) . In LnCaP cells, all constructs showed an high MFI with transduction efficiency reaching 90%. At the maximum viral input, the Prob þ PSE construct displayed extremely high expression, with a MFI around 6500, whereas the experiments using the PSA-1 þ PSE showed intermediate level, slightly higher than the positive control RRL-PGK-GFP-Sin18, with a MFI of 1500 and 800, respectively. The PSMA-2.5 þ PSE construct showed a level of expression similar to RRL-PGK-GFP-Sin18 with an MFI below 500 even at high viral input. A noteworthy finding was that in both cell types the number of EGFP-positive cells increased according to the viral input (Figure 5a and b) . In HuH7, when using RRL-PGK at a dose of 400 ng of p24 level, MFI was around 420 in transduced cell populations with 91% of EGFP-positive cells. As expected, MFIs in HuH7 cells transduced with lentiviral vectors containing a chimeric prostate-specific expression unit remained at the basal level (between 20 and 44). Even at the highest dose of p24, low MFI was observed for the PSMA-2.5 þ PSE and Prob þ PSE constructs. The percentage of EGFP-positive PSA enhancer core element in lentiviral vectors S Chapel-Fernandes et al cells ranged from 3 to 15% for PSMA-2.5 þ PSE and Prob þ PSE constructs, whereas it reached 53% for the PSA-1 þ PSE construct. These findings indicate that the three PSE-based constructs tested retained their prostate-specific capabilities in a context mimicking transduction level obtained after intratumoral injection. The Prob þ PSE construct appeared to be strictly tissue-specific, as it was found to be faintly expressed in the non-prostate cell line while reaching a very high intensity in the LnCaP cells. The PSA-1 þ PSE and PSMA-2.5 þ PSE constructs were also prostate-specific with the expression levels in LnCap being comparable in intensity to those achieved with the ubiquitously expressed control PGK in HuH7 and LnCaP.
Combination of the PSE element and basal promoter in a lentiviral context did not abolish androgen response To ascertain whether the combination of elements of various origins, including the lentiviral backbone, could alter the putative androgen-dependent regulation conferred by the PSE element, the LnCaP and HuH7 cells were grown in the presence of charcoal-stripped serum and then transduced with a low viral input. One day after the transduction, cells were treated with increasing amounts of R1881, a non-metabolizable androgen analogue (1-5-10 nM). Seven days following the initiation of androgen treatment, the intensity of EGFP fluorescence by MFI and percentage of EGFP-positive cells were monitored by FACS analysis. In LnCaP cells (Figure 5a) , all concentrations of R1881 tested markedly improved the activity of the prostatespecific chimeric promoters compared to the mock treatment, without affecting the expression of the PGK control promoter. In the presence of R1881, a fivefold and 20-fold increase of the MFI was observed for PSA-1 þ PSE or PSMA-2.5 þ PSE and for Prob þ PSE, respectively, whereas a twofold increase in the percentage of EGFP-positive cells was observed. Induction factors were similar regardless of hormonal concentration with 10 nM R1881 being slightly less effective. In HuH7 (Figure 5b ), as expected, the R1881 treatment had no impact on EGFP expression, of any construct tested. Fluorescence microscopy analysis (data not shown) showed that induction of EGFP expression by androgen in LnCaP is rapid, as a clearcut difference between treated and mocktreated cells appeared within 16 h after addition of hormone. A linear increase was observed for approximately 6 days, at which time expression level reached a plateau, and remained constant for 14 days. These observations were confirmed by FACS analysis (data not shown).
Addition of the central polypurine tract region had no effect on tissue-specific expression of PSE element-containing chimeric promoters and did not improve transduction efficiency The central polypurine tract region/central termination site, cPPT/CTS, has been reported to act as a cis-active determinant of human immunodeficiency virus (HIV)-1 genome nuclear import and to dramatically increase gene transduction efficiency in a variety of non-dividing cells by increasing the amount of integrated vector DNA. [37] [38] [39] [40] Previous experiments performed in the laboratory have shown that the RRL vector backbone used to generate RRL-PGK-GFPsin18, which does not contain the cPPT/ CTS, favors the transduction of hepatocarcinoma cells versus normal hepatic cells (data not shown), suggesting that, although less efficient, a vector devoid of cPPT/CTS can be selected to improve targeting of the tumor cells. These data led us to select the RRL vector backbone devoid of cPPT/CTS as a preliminary step, to construct the lentiviral vectors tested in this study.
Experiments were performed to determine the possible advantages of including cPPT/CTS in composite vectors used in a lentiviral vector context. The HIV-1 cPPT/CTS was combined with the positive control PGK promoter (PGK þ cPPT/CTS), with the basal PSA promoter (PSA-1 þ cPPT/CTS) and its chimeric version containing the PSE (PSA-1 þ PSE þ cPPT/CTS), with the elongated form of the PSA promoter (PSA-3.2 þ 2.5 þ cPPT/CTS), and with the chimeric version of the probasin promoter associated with the PSE (Prob þ PSE þ cPPT/CTS) (Figure 1) . The impact of the cPPT/CTS sequence on the transduction efficiency and expression levels was tested in non-prostate cells HuH7 and in LnCaP cells using a low viral input (data not shown). Interestingly, transduction was increased only with the combination of the cPPT/ CTS and the PGK promoter (PGK þ cPPT/CTS). No significant gain or loss of transduction efficiency was observed whether cPPT/CTS was present or not in the prostate-specific lentiviral vectors described in this study. Similar results were obtained using PNT2C2 cell line as target (data not shown).
Discussion
Lentiviral vectors have previously been tested with various types of target cells or tissues, including prostate cancer cells, with encouraging results. 41 In this study, in vitro expression of various combinations of minimal promoter sequences with regulatory elements known to specifically drive expression of the PSA gene in prostate cells was assayed in a lentiviral vector context. 15, 42 Promoter regions of the human PSA gene, human pTG gene human PSMA gene, rat probasin gene and human PGK gene were fused with the PSE element to select vectors able to drive tissue-specific expression that is strong in prostate cells and low or absent in non-prostate cells.
Our results indicated that the 0.2 and 1.4 kb long pTG promoter regions are weak basal promoters when included in a lentiviral vector. The combination of the pTG basal promoter with the PSA enhancer did not confer either tissue specificity or androgen responsiveness (data not shown). It is known that pTG is not expressed in LnCaP or, more generally, in prostate cancer cells and most metastatic tissues. [4] [5] [6] These results differ from those published by An et al., 4 who claimed that certain elements in the 1.4 kb proximal region are sufficient to drive prostate-specific expression in PC3PF cells. Conversely, these data are in agreement with those published by Dubbink 43 showing that even the first 2.1 kb sequence of the promoter region alone confers basal expression in PC346C cells transiently transfected with plasmid vectors. Interestingly, these results demonstrate that the vector backbone, which contains functional residual promoter elements as described recently, 44 does not have a major influence on expression of the EGFP gene in LnCaP cells and suggest that the increased expression observed in such a vector backbone could account for transcription of the EGFP gene from the internal promoter.
As expected from previous study, 12 vectors including the 1 or 2.5 kb long PSMA promoter regions did not show relevant tissue-specific expression in our model. Although a slight repression was observed in both hepatocarcinoma cells and LnCaP when comparing the 2.5 kb to the 1 kb construct, the two versions could not be considered as tissue-specific promoters. When the PSA enhancer was associated with the 2.5 kb long PSMA upstream sequence, more relevant tissue-specific expression was observed with both low and high viral vector input. In the composite version, hormonal regulation was also achieved after induction of EGFP expression in the presence of R1881. As endogenous PSMA expression is known to be downregulated by androgens, it was concluded that androgen response depends on PSA enhancer activity. It would be interesting to test an additional PSMA enhancer that has been characterized in the third intron about 12 kb downstream of the transcription start site. 45, 46 Even though the 3.2 kb of the PSA promoter region contains both proximal AREs, 13, 47 only basal expression was obtained when the 3.2 kb of the PSA promoter region was selected as an internal promoter in a lentiviral context. Results obtained with PSA-1, which contains the first 1 kb of the promoter region, are in accordance with those of Latham et al. 48 but differ from those of Pang et al., 14 who reported tissue-specific and androgeninduced expression using a short 620 bp region similar to the 600 bp region assayed in PSA-0.6. Interestingly, the 3.2 kb fragment of the PSA promoter region contained in PSA-3.2 showed lower basal activity than PSA-1 and PSA-0.6 both in prostate and non-prostate cell lines. The most likely explanation for this finding is interaction of the added region with a more complete set of transcription factors implicated in the endogenous gene regulation. Such interaction could also contribute to silencing in non-prostate tissue.
When the PSA enhancer was included in these constructs, unambiguous tissue specificity and androgen response to hormonal stimulation are recovered, thus confirming that the upstream enhancer was essential for the specific activity of the PSA promoter. 16, 47 Previous studies have also established that androgen receptors bind cooperatively to AREs in the PSE and act synergistically with androgen receptors bound to the proximal promoter to regulate transcriptional output. 16 The results presented here support the latter hypothesis. Conversely, the low level of activity observed with the lentiviral construct using the entire PSA promoter region as a 6 kb long fragment, that is, PSA-3.2 þ 2.5, in LnCap was surprising in light of the results presented by Cleutjens et al. 42 These authors reported that three independent transgenic lines carrying a LacZ reporter gene under the control of the 6 kb PSA promoter fragment showed hormonally and developmentally regulated expression of the transgene exclusively targeted to the luminal epithelial cells of the lateral prostate. This expression mimicked the pattern of the endogenous PSA gene in the human prostate.
The Prob þ PSE construct driving the EGFP gene under the combined control of the proximal promoter of the rat probasin gene and the PSA enhancer exhibited high tissue specificity at all viral vector inputs tested. It is noteworthy that the proximal probasin promoter alone also showed strict prostate specificity although to a lesser extent. 19, 36, 49 It should also be pointed out that the activity of this promoter was partially dependent on two AR-binding sites, that is, ARBS-1 (located at position À236 to À223) and ARBS-2 (at position À140 to À117) that constitute the androgen-response region (ARR) (located between À244 and À96 bp of the probasin promoter) required for maximal androgen induction of expression. 20, 50 The fact that the activity of probasin promoter increased dramatically after addition of the PSA enhancer suggests that these two regulating regions function cooperatively.
Taken altogether, these data suggest that various cofactors in addition to androgen receptors are necessary for promoters to achieve tissue-specific and androgendependent regulation of expression when AREs are present in the proximal region. Expression ranged from faint with no improvement when the PSA enhancer was used to intense prostate specific with strong androgeninduced capacity combined with weak activity in nonprostate cells. The combination of the PSA enhancer and the rat probasin promoter showed both strong specificity and high level of EGFP expression. Further study will be necessary to determine whether the observed basal activity depends on faint basal transcription originating from the internal tissue-specific promoter or on residual promoter activity of the lentiviral vector backbone, as recently reported by Logan et al. 44 The cPPT/CTS located in the central position in all lentiviral genome has been generally believed to enhance nuclear import and thereby drastically stimulate lentiviral vector transduction efficiency. 37, 40, 51 At least in vitro, the cis-active cPPT/CTS sequence failed to improve either transduction efficiency or expression level (data not shown). Further study will be needed to determine whether this discrepancy depends on non-central location of cPPT/CTS in all the constructs tested, on unexpected interactions between cPPT/CTS and the promoter sequence, or on complex differences in expression and copy number in transduced cells.
In conclusion, the data described herein suggest that key elements derived from promoters driving tissuespecific expression can efficiently confer or improve tissue-specific expression in a lentiviral context. Accordingly, it may be possible to construct lentiviral vectors with promoters containing transcriptional elements active in distinct tissues. In this way, it would be possible to adjust the spectrum of expression in complex tissues. Therapy), and by the GVPN (Gene Vector production Network). p8.91 and pRRL-PGK-EGFPsin18 were kindly provided by D Trono (University of Geneva, Switzerland). pLucPSEProb was kindly provided by J Trapman (Erasmus university, Rotterdam, The Netherlands).
